Health, pharma and science writer at Reuters. Any opinions are mine.

Sanofi diabetes drug Toujeo wins EU green light, pricing in focus — Credit: Reuters/Charles Platiau French drugs firm Sanofi's logo is pictured inside the company's headquarters during the company's 2014 annual results presentation in Paris February 5, 2015. The positive decision from a committee of experts at the European Medicines Agency had been expected and will pave the way for the long-lasting insulin product to go on sale soon in Sanofi's chosen first European markets of Germany and Britain.

Nikon pushes into medtech with $400 million Optos acquisition — Nikon has previously said it intended to enter the medical sector to leverage its optical technologies and the Japanese group sees buying Optos as an important step in that long-term growth plan. Kazuo Ushida, president of Nikon, said the company would expand the medical business further in the future.

AstraZeneca to carve out antibiotic R&D into separate firm — Credit: Reuters/Darren Staples A sign is seen at an AstraZeneca site in Macclesfield, central England April 28, 2014. Chief Executive Pascal Soriot said last year he was looking to partner or sell its anti-infective business, which is no longer viewed as a core area for the British drugmaker.

Sanofi diabetes drug awaits imminent EU green light — Toujeo is a more potent follow-up to the French drugmaker's top-selling Lantus insulin product, which accounts for a fifth of group sales, and the new drug is pivotal to Sanofi's diabetes business as Lantus faces loss of patent protection.

FDA postpones key hearing on biosimilar copy of blockbuster drug — The U.S. regulator said in a statement on its website late on Wednesday that the hearing was postponed "due to information requests pending with the sponsor of the application". South Korean firm Celltrion and its partner Hospira want to sell Remsima in the United States as a cut-price copy of Johnson & Johnson and Merck & Co's branded drug Remicade.

Biosimilar copies of blockbuster drug launch in major EU markets — The products from South Korean firm Celltrion and its partners Hospira and Mundipharma will compete with Remicade, the original branded drug from Johnson & Johnson and Merck & Co. The potential of biosimilars to grab substantial business from original brands was a key factor behind Pfizer's decision this month to buy Hospira for about $15 billion.

Biosimilar copies of blockbuster drug launch in major EU markets — Biosimilars launched by Celltrion, Hospira and Mundipharma * New products are copies of J&J and Merck's Remicade * Biosimilars expected to disrupt market for biotech medicines By Ben Hirschler LONDON, Feb 25 (Reuters) - Cheap versions of a top-selling drug for rheumatoid arthritis and Crohn's disease are being launched across major European markets in an important advance for a new type of medicines known as biosimilars.

AstraZeneca will buy Actavis lung drugs — London - AstraZeneca said on Thursday it had agreed to buy Actavis's branded respiratory drug business in the United States and Canada for an initial $600 million as it reported weak fourth-quarter earnings.

AstraZeneca to buy Actavis lung drugs as earnings fall short — Credit: Reuters/Phil Noble A sign is seen at an AstraZeneca site in Macclesfield, central England May 19, 2014. AstraZeneca, which is seeking external deals to ensure growth, will also pay another $100 million after Actavis agreed to a number of changes to ongoing collaborations between the two firms. Britain's second-biggest drugmaker posted fourth-quarter results that fell short of expectations and said 2015 sales revenue would decline by a mid single-digit percent at constant exchange rates.

GSK gives roadmap for potential 2016 listing of HIV drugs business — LONDON (Reuters) - GlaxoSmithKline (GSK.L) has hired Citi, Goldman Sachs and Morgan Stanley as financial advisers on its ViiV Healthcare unit as the drugmaker explores a partial initial public offering (IPO) of its HIV medicines unit, sources familiar with the matter said.
More Articles →
Feb 24, 2015

Exclusive: Rare disease drugmaker #PTC Therapeutics explores sale - sources $PTCT

Feb 23, 2015

#Sanofi under fire in #France over new CEO's pay package - #Brandicourt could pocket golden hello of 4 million euros

Feb 23, 2015

The M&A juggernaut keeps rolling as Canada's #Valeant to acquire #Salix in $10.1 billion deal

Feb 05, 2015

Changing of the guard at U.S. #FDA as source tells #Reuters that Commissioner Margaret #Hamburg to step down #pharma

Are You a Journalist?

Make a Portfolio

Create a free Muck Rack account to customize your profile and upload a portfolio of your best work.


For instructions on how to pitch Ben Hirschler, email

Share This Profile